{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=39",
    "query": {
      "intervention": "Dose level 3",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 17835,
    "total_pages": 1784,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T15:12:17.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02841761",
      "title": "A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Midalozam",
          "type": "DRUG"
        },
        {
          "name": "Aprocitentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2016-07-01",
      "completion_date": "2016-10-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-29",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02841761"
    },
    {
      "nct_id": "NCT04869761",
      "title": "Stem Cell Therapy for Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus, Type 1",
        "Diabetes Mellitus",
        "Diabetic Nephropathies"
      ],
      "interventions": [
        {
          "name": "Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LaTonya J. Hickson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-10-07",
      "completion_date": "2023-04-26",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04869761"
    },
    {
      "nct_id": "NCT06115642",
      "title": "A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Malignant Solid Tumors"
      ],
      "interventions": [
        {
          "name": "HLX43",
          "type": "DRUG"
        },
        {
          "name": "HLX10",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 367,
      "start_date": "2023-11-24",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06115642"
    },
    {
      "nct_id": "NCT00326170",
      "title": "Phase II 5-Azacytidine Plus VPA Plus ATRA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome",
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "5-Azacytidine (5-aza)",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "All-Trans Retinoic Acid (ATRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2012-06-15",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00326170"
    },
    {
      "nct_id": "NCT02908269",
      "title": "Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone High-Dose, vaccine, 2016-2017 formulation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2016-09-15",
      "completion_date": "2016-12-09",
      "has_results": true,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 2,
      "location_summary": "Bardstown, Kentucky • Metairie, Louisiana",
      "locations": [
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02908269"
    },
    {
      "nct_id": "NCT03381196",
      "title": "A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza A"
      ],
      "interventions": [
        {
          "name": "Pimodivir 600 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SOC Treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "13 Years to 85 Years"
      },
      "enrollment_count": 553,
      "start_date": "2018-01-21",
      "completion_date": "2020-08-24",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 140,
      "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "California City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03381196"
    },
    {
      "nct_id": "NCT00272961",
      "title": "A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resistant Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TBC3711",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-01",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00272961"
    },
    {
      "nct_id": "NCT01375842",
      "title": "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 661,
      "start_date": "2011-06-21",
      "completion_date": "2018-09-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-11",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375842"
    },
    {
      "nct_id": "NCT00805870",
      "title": "The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Damage",
        "Muscle Inflammation"
      ],
      "interventions": [
        {
          "name": "Lovaza (omega-3-acid ethyl esters)",
          "type": "DRUG"
        },
        {
          "name": "Wheat Germ Oil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Western Michigan University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-03",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2012-09-05",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805870"
    },
    {
      "nct_id": "NCT07727473",
      "title": "Preoperative Semaglutide Prior to Radical Prostatectomy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Semaglutide 2.4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Banner Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2026-07",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-16T15:12:17.606Z",
      "location_count": 1,
      "location_summary": "Gilbert, Arizona",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07727473"
    }
  ]
}